HHCYH 33
Alternative Names: CYH 33; HH-CYH33Latest Information Update: 28 Jul 2024
At a glance
- Originator Shanghai Institute of Materia Medica
- Developer HaiHe Biopharma
- Class Antineoplastics; Carbamates; Fluorinated hydrocarbons; Morpholines; Piperazines; Pyridines; Pyrroles; Small molecules; Sulfones; Triazines
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I Breast cancer; Gynaecological cancer; Prostate cancer; Solid tumours
- No development reported Oesophageal cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Unknown (PO)
- 31 May 2024 Efficacy and adverse events data from a phase Ib trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)